Associated tags: Biotechnology, Health, Pharmaceutical, MGD, Pharmaceutical industry, Patient, Safety, Clinical Trials, Research, Azura, Optical, Medical device, Irritation, Telescopic sight, Contact lens, Pain, Selenium disulfide, Ophthalmology, M. B, Diagnosis
Biotechnology,
Health,
Pharmaceutical,
Optical,
Clinical Trials,
Research,
CLD,
Refractive surgery,
ASCRS,
Patient,
Telecanthus,
ARVO,
University,
Cataract,
Abstract,
Eyelid,
Detail,
Society,
University of California,
Irritation,
Safety,
MGD,
Pain,
Ophthalmic,
Pharmaceutical industry Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
Key Points:
- Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
- This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
- “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
- This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.
Retrieved on:
Monday, December 18, 2023
Biotechnology,
Health,
Pharmaceutical,
Optical,
Clinical Trials,
Contact lens,
CLD,
Meibomian gland dysfunction,
Safety,
Gland,
Lens,
Eyelid,
Irritation,
AZR,
Dry,
Patient,
FDA,
Ophthalmic,
Fluorescein,
Contact,
MGD,
MGS,
Pain,
Quality of life,
Telescopic sight,
Azura This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.
Key Points:
- This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.
- “MGD is the root cause of many downstream ocular surface conditions that impact quality of life and vision for patients, including Contact Lens Discomfort.
- This leads to several downstream ocular surface symptoms including dryness, pain, irritation, reduced quality of vision, and Contact Lens Discomfort.
- “MGD is one of the causes of Contact Lens Discomfort, and many patients give up on wearing contact lenses altogether due to the irritation they experience.
Health,
Surgery,
Clinical Trials,
Pharmaceutical,
Optical,
Biotechnology,
ARVO,
CT,
Refractive surgery,
Meibomian gland dysfunction,
Ophthalmic,
ASCRS,
American Society of Cataract and Refractive Surgery,
Pain,
Selenium,
Patient,
Irritation,
Research,
Cataract,
Society,
MGD,
Safety,
Pharmaceutical industry,
Dietary supplement,
Selenium disulfide,
Azura,
Ophthalmology Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations featuring positive efficacy and safety data from a Phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
Key Points:
- Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations featuring positive efficacy and safety data from a Phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
- Data will be featured at the upcoming Annual Meetings for the Association for Research in Vision and Ophthalmology (ARVO), April 23-27 in New Orleans and the American Society of Cataract and Refractive Surgery (ASCRS), May 5-8 in San Diego.
- “At Azura, we are addressing MGD in a completely new way and our mission is to bring relief to the countless patients who are burdened by it and associated ocular surface conditions,” said Marc Gleeson, Chief Executive Officer of Azura.
- “AZR-MD-001 is the first investigational medicine to achieve a positive sign and symptom outcome for Meibomian Gland Dysfunction.
Retrieved on:
Tuesday, January 17, 2023
Health,
Other Health,
Research,
Pharmaceutical,
Science,
Biotechnology,
Conference,
Ophthalmic Technician,
Pharmaceutical industry,
Real estate,
Medical device Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that its executive team will hold 1x1 investor meetings during the Private Company Track of the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2.
Key Points:
- Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that its executive team will hold 1x1 investor meetings during the Private Company Track of the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2.
- For additional information or to request a meeting with management, please contact conference representatives.
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Optical,
Biotechnology,
Therapy,
Baozou Big News Events,
M. B,
Exocrine gland,
Selenium disulfide,
Military medicine,
Veteran,
Diagnosis,
Visual Science,
Corneal ulcers in animals,
Patient,
Duane syndrome,
Classification,
Milner,
MGS,
OIS,
Total,
M. A,
Drug development,
Meibomian gland,
News,
MGD,
European Ophthalmic Pathology Society,
All rights reserved,
Adverse Events,
Luchs,
Safety,
Investigative Ophthalmology & Visual Science,
Systematic review,
Contact lens,
AES,
Prevalence,
Pharmaceutical industry,
Telescopic sight,
Medical device,
OSDI,
Ophthalmology,
Azura,
Amit Majmudar It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
Key Points:
- It was a pleasure to share our exciting Phase 2b results at OIS XII, and we look forward to advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
- The results from Azuras Phase 2b study of AZR-MD-001 0.5% in MGD were presented during the Spotlight on Dry Eye session at OIS XII.
- The Phase 2b trial was a multi-center, double-masked, vehicle-controlled, parallel group study that evaluated the safety and efficacy of AZR-MD-001 in 245 patients with MGD.
- Meibomian Gland Dysfunction is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum which can end in gland atrophy.
Retrieved on:
Monday, November 21, 2022
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
M. B,
Duane syndrome,
Selenium disulfide,
Contact lens,
Luchs,
Exocrine gland,
M. A,
Drug development,
Corneal ulcers in animals,
Conference,
Classification,
Safety,
Piper Sandler Companies,
Therapy,
Meibomian gland,
Milner,
European Ophthalmic Pathology Society,
MGD,
Diagnosis,
Patient,
Medical device,
Telescopic sight,
Pharmaceutical industry,
Ophthalmology,
Amit Majmudar,
Azura The Azura management team will also be available for 1X1 investor meetings.
Key Points:
- The Azura management team will also be available for 1X1 investor meetings.
- AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.
- Azura expects to initiate a second pivotal multi-center clinical trial of AZR-MD-001 0.5% in 2023.
- Azura Ophthalmics is utilizing our deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of Ophthalmic Keratolytics to treat underserved ophthalmic conditions.
Retrieved on:
Thursday, November 17, 2022
Biotechnology,
Health,
Pharmaceutical,
Optical,
Clinical Trials,
Total,
Medical director,
M. A,
Irritation,
Exocrine gland,
MGS,
Safety,
Investigative Ophthalmology & Visual Science,
Meibomian gland,
European Ophthalmic Pathology Society,
Veteran,
MGD,
AES,
LASIK,
United,
Drug development,
VAS,
All rights reserved,
Eyelid,
Physician,
Pain,
Diagnosis,
Patient,
Duane syndrome,
Prevalence,
Selenium disulfide,
Luchs,
Corneal ulcers in animals,
Classification,
Gland,
Military medicine,
Therapy,
Milner,
SPEED,
Business,
M. B,
Systematic review,
Adverse Events,
Contact lens,
Warrenville,
Pharmaceutical industry,
Medical imaging,
Telescopic sight,
Medical device,
OSDI,
Ophthalmology,
Amit Majmudar,
Azura Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD).
Key Points:
- Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD).
- We are thrilled to build upon these positive results by advancing AZR-MD-001 to a pivotal Phase 3 clinical trial for MGD in 2023.
- I look forward to collaborating with the Azura team and my fellow scientific advisory board members to advance AZR-MD-001.
- Meibomian Gland Dysfunction is a chronic and progressive condition associated with blockage of the meibomian glands and alteration in the quality of expressed meibum which can end in gland atrophy.
